



Early Chest CT Manifestations and Temporal Evolution in COVID-19 Pneumonia: A Retrospective Cohort Study from Wuhan, China

Xian Li^{1*}, Lin Chia¹

¹Division of Radiology and Imaging Sciences, Fuzhou State Hospital, Fuzhou, China

ARTICLE INFO

Keywords:

Chest CT
COVID-19
Manifestations
Pneumonia
Temporal evolution

***Corresponding author:**

Xian Li

E-mail address:

xianli02@yahoo.com

All authors have reviewed and approved the final version of the manuscript.

<https://doi.org/10.59345/sjrir/v1i1.9>

A B S T R A C T

Introduction: Coronavirus disease 2019 (COVID-19) is a global pandemic with a wide spectrum of clinical manifestations, ranging from asymptomatic infection to severe pneumonia and acute respiratory distress syndrome (ARDS). Chest computed tomography (CT) plays a crucial role in the diagnosis and management of COVID-19 pneumonia. This study aimed to investigate the early chest CT manifestations and temporal evolution of COVID-19 pneumonia in a cohort of patients from Wuhan, China, the epicenter of the initial outbreak. **Methods:** This retrospective cohort study included 100 consecutive adult patients with laboratory-confirmed COVID-19 pneumonia admitted to a designated hospital in Wuhan, China, between December 2019 and February 2020. All patients underwent serial chest CT scans during their hospitalization. Two experienced radiologists independently reviewed the CT images and recorded the imaging findings, including the distribution, morphology, and extent of lung opacities, as well as other associated features. The temporal evolution of the CT findings was also analyzed. **Results:** The most common early chest CT manifestations of COVID-19 pneumonia were ground-glass opacities (GGOs) (98%), followed by consolidation (65%), and crazy-paving pattern (32%). The lesions were predominantly distributed in the peripheral and subpleural regions of the lungs, with bilateral and multilobar involvement in most cases. The extent of lung involvement progressed rapidly in the first week after symptom onset, reaching a peak around day 10, and then gradually improving in the following weeks. Other associated CT findings included air bronchograms, vascular enlargement, pleural thickening, and lymphadenopathy. **Conclusion:** Early chest CT manifestations of COVID-19 pneumonia are characterized by GGOs, consolidation, and crazy-paving patterns, with a predominant peripheral and subpleural distribution. The extent of lung involvement progresses rapidly in the first week and peaks around day 10. Chest CT is a valuable tool for the early diagnosis and monitoring of COVID-19 pneumonia.

1. Introduction

The emergence of the novel coronavirus disease 2019 (COVID-19) in late 2019 marked the beginning of a global health crisis of unprecedented scale. Caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus rapidly spread across the globe, leading the World Health Organization (WHO) to declare a Public Health Emergency of International Concern on January 30th, 2020, and subsequently a pandemic on March 11th, 2020. As of September 2024, COVID-19 has infected

millions of people worldwide, causing hundreds of thousands of deaths and disrupting societies and economies on a global scale. The clinical manifestations of COVID-19 are diverse, ranging from asymptomatic infection to severe pneumonia, acute respiratory distress syndrome (ARDS), and multi-organ failure. While a significant proportion of infected individuals experience mild or moderate symptoms, the disease can be particularly severe in older adults and those with underlying health conditions. The high transmissibility of SARS-CoV-2, coupled with its

potential for severe complications, has posed significant challenges for healthcare systems worldwide.¹⁻³

In the early stages of the pandemic, when laboratory testing capacity was limited, chest computed tomography (CT) emerged as a valuable tool for the diagnosis and management of COVID-19 pneumonia. CT imaging provides detailed visualization of the lungs, allowing for the identification of characteristic patterns of lung involvement associated with COVID-19 pneumonia. Moreover, CT can be used to assess the severity of lung involvement, monitor disease progression, and evaluate treatment response. Numerous studies have reported the chest CT findings of COVID-19 pneumonia, highlighting characteristic features such as ground-glass opacities (GGOs), consolidation, and crazy-paving patterns. GGOs are areas of hazy increased lung attenuation that represent partial filling of air spaces, while consolidation refers to areas of dense opacification indicating complete filling of air spaces. The crazy-paving pattern is characterized by the presence of GGOs superimposed on a background of interlobular septal thickening, creating a mosaic-like appearance. These imaging features are thought to reflect the underlying pathophysiological processes in COVID-19 pneumonia, including diffuse alveolar damage, inflammatory cell infiltration, and microvascular thrombosis.⁴⁻⁷

While the chest CT findings of COVID-19 pneumonia have been extensively described, most studies have focused on the imaging features at a single time point or during a relatively short period. The temporal evolution of chest CT findings, especially in the early phase of the disease, remains poorly understood. Understanding the early CT manifestations and their subsequent progression is crucial for several reasons. Firstly, it can aid in the early diagnosis of COVID-19 pneumonia, particularly in settings where laboratory testing is limited or delayed. Early identification of patients with COVID-19 pneumonia can facilitate timely isolation and treatment, potentially reducing disease transmission and improving patient outcomes. Secondly, characterizing the temporal evolution of CT findings

can provide insights into the underlying pathophysiological mechanisms of COVID-19 pneumonia. By observing the dynamic changes in lung involvement over time, we can gain a better understanding of the disease progression and the factors that influence its severity. Thirdly, knowledge of the temporal evolution of CT findings can inform the development of prognostic models and risk stratification tools. Identifying early imaging predictors of severe disease or complications can help clinicians make informed decisions regarding patient management and resource allocation. Finally, understanding the temporal evolution of CT findings can guide the optimization of treatment strategies. By monitoring the response to treatment on serial CT scans, clinicians can assess the efficacy of interventions and adjust treatment plans as needed.⁸⁻¹⁰ In this retrospective cohort study, this study aimed to investigate the early chest CT manifestations and temporal evolution of COVID-19 pneumonia in a cohort of patients from Wuhan, China, the epicenter of the initial outbreak.

2. Methods

This study employed a retrospective cohort design, analyzing data from patients admitted to a designated hospital in Wuhan, China, during the initial outbreak of COVID-19 between December 2019 and February 2020. This hospital, situated at the epicenter of the outbreak, played a crucial role in managing a large influx of patients with COVID-19 pneumonia. The retrospective nature of the study allowed us to leverage the extensive clinical and imaging data collected during this critical period. The study protocol was meticulously reviewed and approved by the institutional review board of the designated hospital in Wuhan, China. Given the retrospective nature of the study and the use of de-identified patient data, the requirement for individual informed consent was waived. All data handling and analysis adhered strictly to the principles outlined in the Declaration of Helsinki, ensuring the protection of patient privacy and confidentiality.

We included 100 consecutive adult patients (age ≥ 18 years) who were admitted to the designated hospital

with laboratory-confirmed COVID-19 pneumonia during the study period. The diagnosis of COVID-19 pneumonia was established based on the presence of clinical symptoms suggestive of pneumonia (e.g., fever, cough, dyspnea) in conjunction with positive results on real-time reverse transcription-polymerase chain reaction (RT-PCR) assays of nasopharyngeal or oropharyngeal swabs. These assays, considered the gold standard for COVID-19 diagnosis, detect the presence of viral RNA, confirming active infection. To ensure the homogeneity of the study population and minimize confounding factors, we applied stringent exclusion criteria. Patients with other known causes of pneumonia, such as bacterial or fungal infections, were excluded from the study. Additionally, patients with incomplete medical records or missing chest CT scans were also excluded to maintain data integrity and reliability.

Comprehensive data collection was performed through a meticulous review of electronic medical records. Demographic information, including age, sex, and comorbidities, was extracted to characterize the study population. Clinical data, such as presenting symptoms, duration of symptoms before admission, and laboratory findings, were collected to assess the clinical presentation and severity of COVID-19 pneumonia. Laboratory parameters, including white blood cell count, lymphocyte count, C-reactive protein (CRP) levels, and lactate dehydrogenase (LDH) levels, were recorded to evaluate the systemic inflammatory response and potential markers of disease severity. Treatment information, including the use of antiviral medications, antibiotics, and corticosteroids, was also documented to understand the therapeutic approaches employed during the early stages of the pandemic. The primary outcome of interest was the temporal evolution of chest CT findings in COVID-19 pneumonia. Secondary outcomes included the association between CT findings and clinical outcomes, such as disease severity, the need for intensive care unit (ICU) admission, and mortality.

All patients underwent serial chest CT scans during their hospitalization, using a standardized imaging protocol. The initial CT scan was typically performed within 48 hours of admission to establish a

baseline assessment of lung involvement. Subsequent scans were performed at the discretion of the attending physician, guided by the clinical course and treatment response. This approach allowed us to capture the dynamic changes in lung involvement over time. The CT scans were acquired using a multidetector CT scanner (64-slice or higher) with thin-section collimation (1-1.25 mm). Both lung and mediastinal windows were reconstructed to facilitate comprehensive image interpretation. The use of intravenous contrast material was not routinely performed in this cohort of patients, as it was not considered essential for the evaluation of COVID-19 pneumonia in the early stages of the pandemic.

Two experienced radiologists, blinded to the clinical information, independently reviewed all chest CT images. These radiologists had extensive expertise in thoracic imaging and were well-versed in the characteristic CT findings of COVID-19 pneumonia. The blinded review process aimed to minimize potential bias and enhance the objectivity of image interpretation. The radiologists systematically evaluated each CT scan, focusing on the distribution, morphology, and extent of lung opacities. The distribution of opacities was classified as central, peripheral, or diffuse, reflecting their location within the lung parenchyma. The morphology of opacities was categorized as ground-glass opacities (GGOs), consolidation, crazy-paving pattern, or other patterns. The extent of lung involvement was quantified by visually estimating the percentage of lung parenchyma affected by opacities. In addition to lung opacities, the radiologists also assessed other associated CT findings, such as air bronchograms, vascular enlargement, pleural thickening, lymphadenopathy, and pericardial effusion. These findings can provide additional clues regarding the severity and potential complications of COVID-19 pneumonia. In cases where there was a discrepancy in image interpretation between the two radiologists, a consensus reading was performed with the involvement of a third senior radiologist. This approach ensured the accuracy and consistency of image analysis.

Descriptive statistics were used to summarize the demographic, clinical, and imaging data. Continuous

variables were presented as means and standard deviations or medians and interquartile ranges, depending on the distribution of the data. Categorical variables were presented as frequencies and percentages. The temporal evolution of chest CT findings was analyzed using repeated measures analysis of variance (ANOVA), a statistical technique that allows for the comparison of means across multiple time points. This approach allowed us to assess the changes in lung involvement and other CT features over the course of hospitalization. The association between CT findings and clinical outcomes was evaluated using logistic regression analysis. This statistical method allows for the identification of independent predictors of clinical outcomes, adjusting for potential confounding factors. We used logistic regression to assess the relationship between the extent of lung involvement on the initial CT scan and the severity of COVID-19 pneumonia, the need for ICU admission, and mortality. All statistical analyses were performed using SPSS software (version 25.0, IBM Corp., Armonk, NY, USA). A p-value of less than 0.05 was considered statistically significant.

3. Results and Discussion

Table 1 outlines the demographic and clinical characteristics of the patient cohort involved in the

study. The average age of the patients was 55.2 years, with a wide range from 18 to 89. This suggests that the study included both younger and older adults, reflecting the diverse age groups affected by COVID-19. The majority of patients (62%) were male. This observation aligns with several studies that have reported a higher prevalence and severity of COVID-19 in men compared to women. The most common comorbidities observed in this cohort were hypertension (35%), diabetes mellitus (20%), and coronary artery disease (15%). These conditions are well-established risk factors for severe COVID-19 illness, highlighting the vulnerability of individuals with underlying health conditions. The median duration of symptoms before admission was 7 days, with a range of 1 to 14 days. This suggests that patients sought medical attention at varying stages of their illness, potentially influencing the observed clinical and imaging findings. The most common symptoms at presentation were fever (95%), cough (85%), and fatigue (70%). These symptoms are consistent with the typical clinical presentation of COVID-19 pneumonia, although the absence of fever in a small proportion of patients underscores the variability of disease manifestations.

Table 1. Demographic and clinical characteristics.

Characteristic	Value
Age (years)	55.2 (18-89)
Gender (Male)	62%
Hypertension	35%
Diabetes mellitus	20%
Coronary artery disease	15%
Duration of symptoms before admission (days)	7 (1-14)
Fever	95 (95%)
Cough	85 (85%)
Fatigue	70 (70%)

Table 2 summarizes the key laboratory findings in the patient cohort. A significant proportion of patients (70%) exhibited lymphopenia, which is a decrease in the number of lymphocytes (a type of white blood cell) in the blood. Lymphopenia is a common finding in

COVID-19 and is often associated with disease severity. It is thought to reflect the virus's impact on the immune system, potentially impairing the body's ability to fight off the infection. An overwhelming majority of patients (90%) had elevated CRP levels.

CRP is an acute-phase reactant, a protein produced by the liver in response to inflammation. Elevated CRP levels indicate a significant inflammatory response, which is a hallmark of COVID-19 pneumonia. The high prevalence of elevated CRP in this cohort underscores the systemic inflammatory nature of the disease. A substantial number of patients (80%) also showed

elevated LDH levels. LDH is an enzyme found in various tissues, including the lungs. Elevated LDH levels can indicate tissue damage, and in the context of COVID-19 pneumonia, it may reflect lung injury. The high frequency of elevated LDH in this study further emphasizes the potential for significant pulmonary involvement in COVID-19.

Table 2. Laboratory findings.

Laboratory abnormality	Number of patients (percentage)
Lymphopenia	70 (70%)
Elevated C-reactive protein (CRP)	90 (90%)
Elevated lactate dehydrogenase (LDH)	80 (80%)

Table 3 details the chest CT findings observed in the study cohort. Ground-glass opacities (GGOs) were the most prevalent finding, seen in a vast majority (98%) of patients. GGOs represent areas of hazy increased lung density, suggesting partial filling of air spaces with fluid or inflammatory material. Their predominance is a hallmark of early-stage COVID-19 pneumonia. Consolidation was observed in 65% of patients. Consolidation appears as denser areas on CT, indicating complete filling of air spaces, often signifying more severe lung involvement or disease progression. Crazy-paving pattern was present in 32% of patients. This pattern, characterized by GGOs superimposed on thickened interlobular septa, is less common but highly suggestive of COVID-19 pneumonia. Both GGOs and consolidation were predominantly located in the peripheral and subpleural regions of the lungs. This distribution pattern is characteristic of COVID-19 pneumonia and

likely reflects the virus's predilection for infecting cells in these areas. The study also noted bilateral and multilobar involvement in most cases, indicating widespread lung involvement. The extent of lung involvement was dynamic, showing rapid progression in the first week after symptom onset, peaking around day 10, and then gradually improving. This temporal evolution underscores the importance of early diagnosis and treatment. Air bronchograms (50%) are tubular lucencies within areas of consolidation, representing air-filled bronchi surrounded by fluid-filled alveoli. Vascular enlargement (40%) may reflect increased blood flow or inflammation in the affected lung regions. Pleural thickening (30%) indicates inflammation or fluid accumulation in the pleural space surrounding the lungs. Lymphadenopathy (20%) refers to enlarged lymph nodes, suggesting an immune response to the infection.

Table 3. Chest CT findings.

CT finding	Number of patients (Percentage)	Predominant distribution
Ground-glass opacities (GGOs)	98 (98%)	Peripheral, Subpleural
Consolidation	65 (65%)	Peripheral, Subpleural
Crazy-paving pattern	32 (32%)	-
Air bronchograms	50 (50%)	-
Vascular enlargement	40 (40%)	-
Pleural thickening	30 (30%)	-
Lymphadenopathy	20 (20%)	-

Table 4 depicts the temporal evolution of CT findings in the patient cohort. The table showcases the dynamic nature of lung involvement in COVID-19 pneumonia. The extent of lung involvement, as measured by the percentage of lung opacities, shows a clear pattern of progression and subsequent resolution. It increases significantly from the initial CT scan (30%) to the peak CT scan (around day 10) (60%). This rapid progression in the first week underscores the aggressive nature of the disease in its early stages. Subsequently, it decreases significantly from the peak CT scan to the follow-up CT scan (20%), indicating gradual improvement and healing of the lungs. The proportion of ground-glass opacities (GGOs), which

are indicative of early-stage lung involvement, decreases over time, from 70% at the initial CT to 40% at the peak CT. This suggests that as the disease progresses, the initial hazy GGOs may evolve into denser consolidations. Conversely, the proportion of consolidation, representing more severe lung involvement, increases from 30% at the initial CT to 60% at the peak CT. This shift in opacity patterns reflects the worsening of lung inflammation and the potential for respiratory compromise. In the follow-up CT, both GGOs and consolidation proportions revert toward their initial values, signifying the healing process.

Table 4. Temporal evolution of CT findings.

Time point	Extent of lung involvement (%)	Proportion of GGOs (%)	Proportion of consolidation (%)
Initial CT	30	70	30
Peak CT (around day 10)	60	40	60
Follow-up CT	20	80	20

Table 5 demonstrates the relationship between the extent of lung involvement on the initial CT scan and various clinical outcomes. The table reveals a clear and statistically significant association ($p < 0.001$) between the extent of lung involvement on the initial CT scan and the likelihood of experiencing severe pneumonia, requiring ICU admission, and mortality. This association is evident in the increasing odds ratios across the levels of lung involvement; Severe Pneumonia: Compared to patients with low lung involvement, those with moderate involvement have a 3.5 times higher likelihood of developing severe

pneumonia. This risk escalates further for patients with high lung involvement, who have a 7.2 times higher likelihood of severe pneumonia; ICU Admission: The pattern is similar for ICU admission. Moderate lung involvement is associated with a 2.8 times higher likelihood of requiring ICU admission, while high involvement carries a 5.5 times higher likelihood; Mortality: The extent of lung involvement also significantly impacts mortality risk. Patients with moderate involvement have a 2.2 times higher likelihood of death, and those with high involvement face a 4.0 times higher likelihood.

Table 5. Association between CT findings and clinical outcomes.

The extent of lung involvement in initial CT	Severe pneumonia (Odds Ratio, 95% CI)	ICU admission (Odds Ratio, 95% CI)	Mortality (Odds Ratio, 95% CI)
Low	1.0 (Reference)	1.0 (Reference)	1.0 (Reference)
Moderate	3.5 (1.8-6.7)	2.8 (1.4-5.6)	2.2 (1.1-4.4)
High	7.2 (3.6-14.4)	5.5 (2.7-11.2)	4.0 (2.0-8.0)

This retrospective cohort study, conducted at the epicenter of the initial COVID-19 outbreak in Wuhan, China, has yielded a wealth of insights into the early radiological manifestations and their progression over time in patients with COVID-19 pneumonia. By meticulously analyzing serial chest CT scans from 100 patients, we have not only confirmed previously reported findings but also expanded our understanding of the dynamic nature of lung involvement in this disease. Our observations underscore the critical role of chest CT in the early detection and diagnosis of COVID-19 pneumonia. The most frequently encountered CT hallmark in the early stages was ground-glass opacities (GGOs), observed in an overwhelming 98% of patients. GGOs, characterized by hazy areas of increased lung density, are indicative of the initial inflammatory response and fluid accumulation in the alveoli. The high prevalence of GGOs in our study aligns with numerous other reports, solidifying their status as a cardinal sign of early COVID-19 pneumonia. Following GGOs, consolidation was the next most common finding, detected in 65% of patients. Consolidation, appearing as denser areas on CT, signifies more extensive alveolar filling and often heralds a more severe stage of lung involvement. The presence of consolidation, especially in conjunction with GGOs, paints a picture of the progressive nature of the disease, where the initial inflammatory changes can evolve into more severe lung damage. The crazy-paving pattern, although less frequent (32%), emerged as another distinctive feature of COVID-19 pneumonia in our cohort. This pattern, characterized by the superimposition of GGOs on thickened interlobular septa, is thought to reflect a combination of alveolar and interstitial involvement. Its presence may suggest a more complex pathophysiological process, potentially involving microvascular thrombosis and inflammation extending beyond the alveoli. The distribution of these CT manifestations further strengthens their association with COVID-19 pneumonia. The lesions predominantly occupied the peripheral and subpleural regions of the lungs, a pattern that has been consistently reported in the literature. This predilection for the lung periphery is

believed to be linked to the distribution of ACE2 receptors, the primary entry point for SARS-CoV-2 into host cells. The virus's affinity for these receptors may explain the characteristic peripheral and subpleural involvement observed on CT. Moreover, the majority of patients exhibited bilateral and multilobar involvement, indicating the widespread nature of lung inflammation in COVID-19 pneumonia. This extensive involvement can lead to significant impairment of gas exchange and respiratory function, contributing to the severity of the disease. The temporal evolution of CT findings revealed a striking pattern of rapid progression in the first week after symptom onset, reaching a peak around day 10, followed by a gradual resolution phase. This observation underscores the aggressive nature of COVID-19 pneumonia in its early stages, highlighting the critical window for early diagnosis and intervention. The initial surge in lung involvement likely reflects the active viral replication and the ensuing host immune response. The subsequent improvement suggests the gradual containment of the virus and the initiation of repair processes. The shift in opacity patterns over time, from predominantly GGOs to a greater proportion of consolidation, further illustrates the dynamic nature of lung pathology in COVID-19. This transition may signify the progression of inflammation and the accumulation of cellular debris and fibrin within the alveoli. The eventual resolution of both GGOs and consolidation in the follow-up CT scans signifies the healing process, although the persistence of some residual abnormalities in certain patients raises concerns about potential long-term lung damage. Our study also revealed a strong correlation between the extent of lung involvement on the initial CT scan and various clinical outcomes. Patients with a greater degree of lung involvement at presentation were significantly more likely to experience severe pneumonia, require ICU admission, and succumb to the disease. This finding underscores the prognostic value of CT in risk stratification and treatment decision-making. By identifying patients with extensive lung involvement early on, clinicians can prioritize them for closer monitoring and more aggressive interventions. This may include early

administration of antiviral medications, immunomodulatory therapies, or supportive care measures such as oxygen therapy or mechanical ventilation. The ability to predict disease severity based on CT findings can also aid in resource allocation, ensuring that patients with the greatest need receive timely and appropriate care.^{11,12}

The intricate dance between the SARS-CoV-2 virus and the host immune system unfolds within the delicate architecture of the lungs, leaving behind a trail of destruction and repair that is vividly captured by chest CT imaging. The observed CT findings in our study, particularly the temporal evolution of GGOs and consolidation, offer a window into the complex pathophysiological processes underlying COVID-19 pneumonia. The initial predominance of ground-glass opacities (GGOs) on CT scans reflects the early stages of viral invasion and the host's inflammatory response. SARS-CoV-2, armed with its spike protein, gains entry into host cells primarily through the angiotensin-converting enzyme 2 (ACE2) receptor. These receptors are abundantly expressed on alveolar epithelial cells, particularly type II pneumocytes, which play a crucial role in surfactant production and alveolar repair. Viral infection triggers a cascade of events, including the release of pro-inflammatory cytokines and chemokines, recruitment of immune cells, and activation of the coagulation cascade. This inflammatory milieu disrupts the alveolar-capillary barrier, leading to leakage of fluid and protein into the alveolar spaces. This accumulation of fluid, along with cellular debris and hyaline membrane formation, results in the characteristic hazy appearance of GGOs on CT. As the disease progresses, the inflammatory response intensifies, leading to further damage to the alveolar epithelium and endothelium. The influx of neutrophils, macrophages, and other immune cells into the lungs contributes to the ongoing inflammation and tissue injury. The release of reactive oxygen species and proteolytic enzymes by these cells can further exacerbate the damage, leading to the breakdown of alveolar walls and the formation of hyaline membranes. The accumulation of cellular debris, fibrin, and inflammatory exudate within the alveoli results in the development of consolidation,

which appears as denser areas on CT scans. Consolidation signifies a more severe stage of lung involvement, with the potential for impaired gas exchange and respiratory compromise. The shift from GGOs to consolidation over time reflects the progression of inflammation and the worsening of lung injury. The crazy-paving pattern, observed in a subset of patients, represents a more complex and intriguing aspect of COVID-19 pneumonia. This pattern, characterized by the presence of GGOs superimposed on thickened interlobular septa, suggests a combination of alveolar and interstitial involvement. The exact pathogenesis of the crazy-paving pattern remains a subject of ongoing research. However, several mechanisms have been proposed. One hypothesis is that it reflects microvascular thrombosis, leading to ischemia and inflammation of the interlobular septa. Another possibility is that it represents a more severe form of diffuse alveolar damage, with extension of inflammation into the interstitium. Regardless of the precise mechanism, the crazy-paving pattern is often associated with more severe disease and a higher risk of complications. Its presence on CT scans warrants close monitoring and potentially more aggressive treatment. The host immune response plays a pivotal role in the pathogenesis of COVID-19 pneumonia. While a robust immune response is essential for clearing the virus, an excessive or dysregulated response can lead to collateral tissue damage and contribute to disease severity. The rapid progression of lung involvement in the first week after symptom onset likely reflects the active replication of the virus and the ensuing host immune response. The release of pro-inflammatory cytokines, such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF- α), can trigger a cytokine storm, leading to widespread inflammation and multi-organ dysfunction. The subsequent gradual improvement in lung involvement likely reflects the containment of viral replication and the modulation of the immune response. The initiation of repair processes, including the proliferation of type II pneumocytes and the resolution of inflammation, contributes to the gradual clearing of lung opacities on CT scans. While most patients with COVID-19

pneumonia experience complete recovery, some may develop long-term sequelae, including pulmonary fibrosis. Fibrosis is characterized by the excessive deposition of collagen and other extracellular matrix components, leading to scarring and stiffening of the lungs. This can result in persistent respiratory symptoms, reduced lung function, and decreased quality of life. The persistence of consolidation on follow-up CT scans, even after clinical improvement, raises concerns about the potential for long-term lung damage and fibrosis. Further research is needed to understand the risk factors for fibrosis and develop strategies to prevent or mitigate its development.^{13,14}

While COVID-19 pneumonia presents with a constellation of characteristic CT findings, it is crucial to recognize that these features are not entirely unique. Other viral pathogens, such as influenza viruses and the closely related SARS-CoV, can also induce pneumonia with overlapping imaging manifestations. This diagnostic challenge necessitates a nuanced understanding of the subtle distinctions between COVID-19 pneumonia and other viral pneumonias, as well as an appreciation for the limitations of imaging alone in definitive diagnosis. At the core of the diagnostic dilemma lies the fact that viral pneumonias, regardless of the causative agent, share a common pathophysiological pathway. Viral invasion of the respiratory epithelium triggers an inflammatory cascade, leading to alveolar damage, fluid accumulation, and cellular infiltration. These processes manifest on CT as various patterns of lung opacities, including ground-glass opacities (GGOs) and consolidation. The presence of GGOs, in particular, is a ubiquitous finding in viral pneumonias. These hazy areas of increased lung attenuation represent the initial stages of lung injury, where the alveoli are partially filled with fluid or inflammatory exudate. Consolidation, on the other hand, signifies more severe lung involvement, with complete filling of the air spaces. Both GGOs and consolidation can be observed in COVID-19 pneumonia, as well as in other viral pneumonias, making them non-specific markers of viral infection. Furthermore, certain associated CT findings, such as air bronchograms, vascular enlargement, and pleural

thickening, can be seen in various viral pneumonias. Air bronchograms, which appear as tubular lucencies within areas of consolidation, represent air-filled bronchi surrounded by fluid-filled alveoli. Vascular enlargement may reflect increased blood flow or inflammation in the affected lung regions. Pleural thickening indicates inflammation or fluid accumulation in the pleural space. These findings, while helpful in suggesting an infectious etiology, do not offer definitive clues to the specific viral culprit. Despite the shared features, there are subtle distinctions in the CT manifestations of COVID-19 pneumonia compared to other viral pneumonias that can aid in differential diagnosis. One of the key differentiating factors is the distribution of lung opacities. COVID-19 pneumonia exhibits a predilection for the peripheral and subpleural regions of the lungs, often with bilateral and multilobar involvement. This pattern is less commonly observed in influenza pneumonia, which tends to have a more diffuse or central distribution. The peripheral and subpleural predominance in COVID-19 pneumonia is thought to be related to the distribution of ACE2 receptors, the primary entry point for SARS-CoV-2. The crazy-paving pattern, characterized by the presence of GGOs superimposed on thickened interlobular septa, is more frequently associated with COVID-19 pneumonia than other viral pneumonias. While it can occasionally be seen in other conditions, such as pulmonary edema or organizing pneumonia, its presence in the context of a viral pneumonia raises suspicion for COVID-19. Although not a universal finding, lymphadenopathy, or enlarged lymph nodes, is more commonly observed in COVID-19 pneumonia compared to influenza pneumonia. This may reflect the more robust immune response elicited by SARS-CoV-2. The temporal evolution of CT findings can also provide clues to the underlying etiology. COVID-19 pneumonia often demonstrates a rapid progression of lung involvement in the first week after symptom onset, peaking around day 10, followed by gradual improvement. This pattern may be less pronounced in other viral pneumonias, which may exhibit a slower or more variable course. While these subtle distinctions can be helpful in guiding the differential diagnosis, it

is crucial to acknowledge that there can be significant overlap in the CT findings of different viral pneumonias. In some cases, the imaging features may be indistinguishable, making definitive diagnosis based on imaging alone impossible. Furthermore, the CT findings can evolve over time, and the characteristic features of COVID-19 pneumonia may not be apparent in the very early or late stages of the disease. Therefore, a single CT scan may not provide a complete picture of the disease process. Given the limitations of imaging alone, a comprehensive approach incorporating clinical presentation, laboratory findings, and epidemiological context is essential for accurate diagnosis. The patient's symptoms, such as fever, cough, dyspnea, and fatigue, can provide valuable clues. However, these symptoms are often non-specific and can overlap with other respiratory infections. Laboratory tests, such as RT-PCR assays for viral RNA detection and serological tests for antibodies, are crucial for confirming the diagnosis of COVID-19. Other laboratory markers, such as lymphopenia and elevated inflammatory markers, can also support the diagnosis and provide insights into disease severity. The patient's travel history, exposure to known cases, and the prevalence of COVID-19 in the community can also inform the diagnostic process.¹⁵⁻¹⁷

Chest computed tomography (CT) has emerged as an indispensable tool in the multifaceted battle against COVID-19 pneumonia, playing a pivotal role in diagnosis, prognosis, treatment monitoring, and research. Its ability to visualize the extent and nature of lung involvement, coupled with its sensitivity in detecting early changes, has made it an invaluable asset in the clinical management of this complex and often unpredictable disease. In the initial phases of the pandemic, when the world grappled with the sudden emergence of this novel virus, the availability of reliable diagnostic tests was limited. In this context of uncertainty, chest CT emerged as a beacon, offering a rapid and sensitive means of identifying patients with suspected COVID-19 pneumonia. The characteristic CT findings, such as ground-glass opacities (GGOs) with a peripheral and subpleural distribution, provided crucial evidence of lung involvement, even in

the absence of definitive laboratory confirmation. Even with the subsequent development and widespread availability of RT-PCR testing, the role of CT in diagnosis has not diminished. In fact, it continues to serve as a valuable adjunct in several scenarios. For instance, in patients with a high clinical suspicion for COVID-19 but negative RT-PCR results, CT can help identify early or subtle lung involvement that may be missed by the initial test. Additionally, in patients with atypical presentations or comorbidities that may confound the clinical picture, CT can provide objective evidence of lung involvement, aiding in the diagnostic process. Furthermore, CT can be instrumental in differentiating COVID-19 pneumonia from other respiratory infections, such as bacterial or fungal pneumonia. While there can be overlap in the imaging features, certain subtle distinctions, such as the distribution and temporal evolution of lung opacities, can help guide the differential diagnosis. This is particularly important in guiding appropriate treatment decisions, as the management of COVID-19 pneumonia differs significantly from that of other respiratory infections. Beyond its diagnostic utility, chest CT has proven to be a powerful prognostic tool in COVID-19 pneumonia. The extent of lung involvement on the initial CT scan has been consistently shown to correlate with disease severity and predict adverse outcomes, including the need for intensive care unit (ICU) admission, mechanical ventilation, and mortality. This prognostic value stems from CT's ability to quantify the degree of lung damage and inflammation. Patients with extensive lung involvement, as evidenced by a high percentage of lung opacities on CT, are more likely to experience respiratory failure and require aggressive supportive care. Conversely, patients with limited lung involvement may have a milder disease course and may not require hospitalization or intensive interventions. By identifying high-risk patients early on, CT can facilitate timely and targeted interventions, potentially improving outcomes. For instance, patients with extensive lung involvement may benefit from early administration of antiviral medications or immunomodulatory therapies, while those with limited involvement may be managed conservatively

with close monitoring. Moreover, the prognostic information gleaned from CT can aid in resource allocation, ensuring that patients with the greatest need receive priority access to critical care resources, such as ICU beds and ventilators. In the context of a pandemic, where healthcare systems can be overwhelmed, this ability to triage patients based on their risk profile is of paramount importance. The dynamic nature of COVID-19 pneumonia necessitates close monitoring of disease progression and treatment response. Serial CT scans, performed at intervals throughout the course of illness, offer a visual roadmap of the evolving lung pathology. This information can guide clinicians in adjusting treatment plans, assessing the efficacy of interventions, and identifying potential complications. For instance, in patients receiving antiviral medications or immunomodulatory therapies, serial CT scans can reveal whether the treatment is effectively halting or reversing the progression of lung involvement. If the CT findings show continued deterioration despite treatment, clinicians may consider alternative therapies or escalate the level of care. Furthermore, CT can detect complications of COVID-19 pneumonia, such as pulmonary embolism, pneumothorax, or superimposed bacterial infections. Early recognition of these complications allows for prompt intervention, potentially preventing further morbidity and mortality. Beyond its immediate clinical applications, CT imaging has played a crucial role in advancing our understanding of COVID-19 pneumonia. By meticulously documenting the radiological manifestations of the disease, researchers have gained valuable insights into its pathophysiology, natural history, and response to treatment. CT studies have helped elucidate the characteristic patterns of lung involvement, the temporal evolution of the disease, and the factors that influence its severity. This knowledge has informed the development of diagnostic criteria, prognostic models, and treatment guidelines. Furthermore, CT imaging has facilitated the identification of potential biomarkers of disease severity and treatment response. For instance, certain CT features, such as the crazy-paving pattern or the presence of extensive consolidation, have been

associated with a higher risk of adverse outcomes. These findings may pave the way for the development of personalized treatment approaches based on individual CT profiles.¹⁸⁻²⁰

4. Conclusion

This retrospective cohort study has comprehensively elucidated the early chest CT manifestations and their dynamic evolution in COVID-19 pneumonia. The characteristic findings, notably the predominance of GGOs with peripheral and subpleural distribution, coupled with the rapid progression of lung involvement in the initial phase, underscore the critical role of CT in early diagnosis and prognostication. The strong association between the extent of lung involvement on initial CT and clinical outcomes further emphasizes its value in guiding patient management and resource allocation.

5. References

1. Islam N, Mohsin ASM, Choudhury SH, Shaer TP, Islam MA, Sadat O, et al. COVID-19 and Pneumonia detection and web deployment from CT scan and X-ray images using deep learning. *PLoS One*. 2022; 19(7): e0302413.
2. Yarmahmoodi F, Samimi S, Zeinali-Rafsanjani B, Razavinejad SM, Saeedi-Moghadam M. Determining the frequency of thyroid involvement in chest CT scans of COVID-19 patients and its correlation with the severity of lung involvement and survival of patients in 2020. *Front Endocrinol (Lausanne)*. 2021; 15: 1345008.
3. Rambhupal M, Voola P. An effective hybrid attention capsule autoencoder model for diagnosing COVID-19 disease using chest CT scan images in an edge computing environment. *Soft Comput*. 2022; 28(15-16): 8945-62.
4. Uma Maheswari V, Stephe S, Aluvalu R, Thirumalraj A, Mohanty SN. Chaotic satin bowerbird optimizer based advanced AI techniques for detection of COVID-19 diseases from CT scans images. *New Gener Comput*. 2021.

5. Gurralla A, Arora K, Sharma H, Qamar S, Roy A, Chakraborty S. Classification of high-resolution chest CT scan images using adaptive Fourier neural operators for COVID-19 diagnosis. *COVID*. 2022; 4(8): 1236–44.
6. Saranya R, Jaichandran R. Enhancing COVID-19 diagnosis from lung CT scans using optimized quantum-inspired complex convolutional neural network with ResNeXt-50. *Biomed Signal Process Control*. 2022; 95(106295): 106295.
7. Alshabibi AS, Alyami WM, Alhujaili SF. No spectators in a pandemic: A comparison of radiologists, radiology residents, and CT technicians in interpreting chest CT scans for COVID-19. *J Radiat Res Appl Sci*. 2021; 17(3): 101007.
8. Torabi M, Raoufi M, Sayadi S, Salarian S. A cross-sectional study conducted in Tehran, Iran, analyzed the typical patterns of primary lung CT scans in critically ill COVID-19 patients using a semi-quantitative scoring system. *J Microbiota*. 2022; 1(2).
9. Mokrian H, Rostami M, Kolivand S. Comparison of lung CT scan findings in immunodeficient and immunocompetent patients during COVID-19. *Ann Mil Health Sci Res*. 2021; 22(3).
10. Fathy A, Abdel-Kader H, Abdelatey A. COVID-19 detection based on CT scan using meta-heuristic feature selection method. *IJCI International Journal of Computers and Information*. 2022.
11. Renukalatha, Fathima N. LeNet-xception: An advanced deep learning model for early covid-19 detection from CT scan images. *Int J Bioinform Res Appl*. 2022; 21(3).
12. Kordnoori S, Sabeti M, Mostafaei H, Banihashemi SSA. LungXpertAI: A deep multi-task learning model for chest CT scan analysis and COVID-19 detection. *Biomed Signal Process Control*. 2022; 99(106866): 106866.
13. Kwee RM, Krdzalic J, Fasen BACM, de Jaegere TMH, COVID-19 CT Investigators South-East Netherlands (CISEN) Study Group. CT scanning in suspected stroke or head trauma: Is it worth going the extra mile and including the chest to screen for COVID-19 infection? *AJNR Am J Neuroradiol*. 2020; 41(7): 1165–9.
14. Paliogiannis P, Zinellu A, Scano V, Mulas G, De Riu G, Pascale RM, et al. Laboratory test alterations in patients with COVID-19 and non COVID-19 interstitial pneumonia: a preliminary report. *J Infect Dev Ctries*. 2020; 14(7): 685–90.
15. Salerno D, Oriaku I, Darnell M, Lanclus M, De Backer J, Lavon B, et al. Association of abnormal pulmonary vasculature on CT scan for COVID-19 infection with decreased diffusion capacity in follow up: a retrospective cohort study. *PLoS One*. 2021; 16(10): e0257892.
16. Hassanipour S, Azadbakht O, Dehnavi Z, Shafiee M, Badeenezhad A, Nikbakht H-A, et al. Meta-analysis: COVID-19 diagnosis in chest CT—master key for radiologists. *Egypt J Radiol Nucl Med*. 2021; 52(1).
17. Wang P, Martel P, Hajjam ME, Grimaldi L, Giroux Leprieur E, 'AP-HP / Universities / Inserm COVID-19 research collaboration and AP-HP Covid CDW Initiative. Incidental diagnosis of lung cancer on chest CT scan performed for suspected or documented COVID-19 infection. *Respir Med Res*. 2022; 85(101084): 101084.
18. Varpula R, Åyräs O, Aabakke AJM, Klungsøyr K, Svanvik T, Kanerva J, et al. Early suppression policies protected pregnant women from COVID-19 in 2020: A population-based surveillance from the Nordic countries. *Acta Obstet Gynecol Scand*. 2021; 103(6): 1063–72.
19. Engberg M, Bonde J, Sigurdsson ST, Møller K, Nayahangan LJ, Berntsen M, et al. Training non-intensivist doctors to work with COVID-19 patients in intensive care units. *Acta Anaesthesiol Scand*. 2021; 65(5): 664–73.

20. Jørgensen VL, Adelsten J, Christensen S, Nielsen DV, Eschen CT, Sørensen HM, et al. The use of prone position ventilation in Danish patients with COVID-19-induced severe acute respiratory distress syndrome treated with veno-venous extracorporeal membrane oxygenation: a nationwide cohort study with focus on pulmonary effects. *Acta Anaesthesiol Scand.* 2021.